Rowan GLP2(T)
A dual GLP-1/GIP receptor agonist analogue. Studied for its additive and synergistic effects on insulin secretion, weight reduction, and metabolic markers compared to single-receptor GLP-1 agonists.
For laboratory and in vitro research purposes only. Not for human consumption.
What is Rowan GLP2(T)?
GLP-2(T) is a research analogue of tirzepatide — a dual GLP-1/GIP receptor agonist that demonstrated greater weight loss in clinical trials than semaglutide alone. GIP (glucose-dependent insulinotropic polypeptide) is the second major incretin hormone, released from gut K cells. When combined with GLP-1 receptor agonism, GIP co-agonism appears to provide complementary benefits through different pathways — particularly in adipose tissue lipolysis and pancreatic beta-cell function. Head-to-head clinical data showed approximately 5% greater weight loss versus semaglutide.
two receptors. more weight loss
than any single agonist.
Tirzepatide — the pharmaceutical dual agonist — showed greater mean weight loss than semaglutide in head-to-head trials. GLP-2(T) is the research analogue for studying why adding GIP receptor agonism to GLP-1 produces additive effects across adipose tissue, the pancreas, and the CNS.
How GLP-2(T) works in research models
GLP-2(T) is a dual agonist targeting both GLP-1 and GIP receptors simultaneously. Both are incretin hormones released postprandially from gut L and K cells. GIP co-agonism appears to augment weight loss and metabolic outcomes beyond GLP-1R agonism alone — through complementary pathways including adipose tissue lipolysis, central appetite suppression, and pancreatic β-cell preservation.
glp-1 + gip.
the research rationale.
GIP receptor activation complements GLP-1 in three areas: augmented adipose lipolysis, preserved pancreatic beta-cell mass, and complementary hypothalamic satiety signals. Together they produce outcomes that neither achieves alone — the focus of ongoing metabolic research.
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.
N Engl J Med · 2021 · PMID: 34170647
Tirzepatide once weekly for the treatment of obesity.
N Engl J Med · 2022 · PMID: 35658024
Clinical analogue research uses once-weekly subcutaneous dosing with dose titration from 2.5 mg upward to 5–15 mg. The titration schedule is important for GI tolerability. Reconstitute per protocol and store at 4°C. Use within 28 days after reconstitution.
You ask, we answer.
GIP receptor activation appears to complement GLP-1 signalling through different adipose, pancreatic, and CNS pathways. Human clinical data with tirzepatide showed greater mean body weight reduction (~20% vs ~15% for semaglutide) in head-to-head comparisons.
GLP-1(S) is a mono-agonist targeting only the GLP-1 receptor (semaglutide mechanism). GLP-2(T) is a dual agonist targeting both GLP-1 and GIP receptors (tirzepatide mechanism), providing additive and potentially synergistic metabolic effects.
GIP (glucose-dependent insulinotropic polypeptide) is released from K cells in the upper small intestine in response to fat and carbohydrate intake. Like GLP-1, it stimulates glucose-dependent insulin secretion. However, GIP also has direct effects on adipocytes and appears to complement GLP-1 signalling through different central and peripheral pathways.
GLP-2(T) is a research analogue with the same dual GLP-1/GIP receptor agonist mechanism as tirzepatide (Mounjaro, Zepbound). It is not the approved pharmaceutical product and is supplied exclusively for laboratory research use only.
Research Use Only
All Rowan Peptides products are intended strictly for laboratory and in vitro research purposes. They are not approved by the FDA and are not intended for human consumption, veterinary use, or any therapeutic application. By purchasing, you agree to our Terms of Service and Indemnity Waiver. Rowan Peptides LLC operates as a chemical supplier only.
Switched to GLP2(T) from GLP1(S) after reading the mechanism differences. Rowan carries both at the same quality level. The fact that both have Janoshik testing is why this brand is staying in my rotation.
Second order. Same quality as the first which matters more than people think. Lot-to-lot consistency is the real test of a research vendor. Rowan is passing it.
The dual GIP/GLP-1 mechanism is what makes tirzepatide research interesting. Rowan's GLP2(T) is properly sourced and the compound data on the page is accurate. COA in the box with the lot number. Clean vial. This is how you do it.
Write a Review